Therapeutic Evaluation of 2% Tea Lotion in Comparison with 5% Zinc Sulfate Solution in the Treatment of  Acne Rosacea

Khalifa E. Sharquie; Adil A. Noaimi; Sarmad A. Al-Hashimy; Mazin M. Al-Salih

doi:10.4236/jcdsa.2014.41009

Home > Journals > Medicine & Healthcare > JCDSA

Journal of Cosmetics, Dermatological Sci... > Vol.4 No.1, February 2014

Therapeutic Evaluation of 2% Tea Lotion in Comparison with 5% Zinc Sulfate Solution in the Treatment of Acne Rosacea ()

Khalifa E. Sharquie, Adil A. Noaimi, Sarmad A. Al-Hashimy, Mazin M. Al-Salih

Department of Dermatology & Venereology, Baghdad Teaching Hospital, Baghdad, Iraq.
Light Therapy Unit, Department of Dermatology & Venereology, Baghdad Teaching Hospital, Baghdad, Iraq.
Scientific Council of Dermatology & Venereology-Iraqi and Arab Board for Medical Specializations, Department of Dermatology & Venereology, College of Medicine, University of Baghdad, Baghdad, Iraq.

DOI: 10.4236/jcdsa.2014.41009 PDF HTML 4,106 Downloads 5,992 Views Citations

Abstract

Background: There are many effective topical and systemic therapies for acne rosacea. Topical zinc sulfate and tea lotion have been used in treatment of acne vulgaris. Objectives: To evaluate effectiveness of 2% tea lotion in comparison with 5% zinc sulfate solution in the treatment of acne rosacea. Patients and Methods: This single, blinded, comparative therapeutic clinical trial was carried out in the Department of Dermatology—Baghdad Teaching Hospital from June 2006-December 2007. Twenty two patients with acne rosacea were divided into two groups and were instructed to apply the following lotions for two months, Group A used 2% tea lotion twice daily while Group B used 5% zinc sulfate solution twice daily. Patient with severe acne rosacea were excluded from the study. Clinical improvement was evaluated every 2 weeks by determination of the disease severity score (Sharquie’s score) before and after treatment. Results: Eighteen patients with acne rosacea completed the study with their ages ranging from 26 - 70 (40.5 ± 10.9) years. For Group A and Group B were 39.7 ± 8.2, 41.2 ± 13.1 years respectively, with eight patients in Group A, ten patients in Group B. Five percent zinc sulfate solution was statistically significant in reducing the disease severity score in acne rosacea, while 2% tea lotion was beneficial but did not reach statistically significant level as zinc sulfate solution. Conclusion: Five percent zinc sulfate solution was a good alternative remedy to be used in patients with acnerosacea.

Keywords

Acne Rosacea; Tea Lotion; Topical Zinc Sulfate Solution

Share and Cite:

K. Sharquie, A. Noaimi, S. Al-Hashimy and M. Al-Salih, "Therapeutic Evaluation of 2% Tea Lotion in Comparison with 5% Zinc Sulfate Solution in the Treatment of Acne Rosacea," Journal of Cosmetics, Dermatological Sciences and Applications, Vol. 4 No. 1, 2014, pp. 60-65. doi: 10.4236/jcdsa.2014.41009.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	T. Roihu and A. L. Kariniemi, “Demodex Mites in Acne Rosacea,” Journal of Cutaneous Pathology, Vol. 25, No. 10, 1998, pp. 550-552. http://dx.doi.org/10.1111/j.1600-0560.1998.tb01739.x
[2]	M. Dahl, “Bacteria Isolated from the Warm Skin of Rosacea Secrete Excessive Lipase,” Annales de Dermatologie et de Vénéréologie, Vol. 129, 2002, pp. 373.
[3]	T. Jansen, U. Kastner, A. Kreuter and P. Altmeyer, “Rosacea-Like Demodicidosis Associated with Aquired Immunodeficiency Syndrome,” British Journal of Dermatology, Vol. 144, No. 1, 2001, pp. 139-142. http://dx.doi.org/10.1046/j.1365-2133.2001.03794.x
[4]	W. D. James, T. G. Berger and D. M. Elston, “Acne in: Andrews Disease of the Skin, Clinical Dermatology,” 10th Edition, WB Sounder Company Philadelphia, 2006, pp. 231-250.
[5]	A. Roussaki, E. Klimi, E. Zafirious and E. Petinaki, “Rosacea and Helicobacter pylori,” Annales de Dermatologie et de Vénéréologie, Vol. 129, 2002, p. 383.
[6]	H. Aizawa and M. Niimura, “Oral Spironolactone Therapy in Male Patient with Rosacea,” Journal of Dermatology, Vol. 19, 1992, pp. 293-297.
[7]	M. R. Robert, “Vitamines and Trace Element Deficiency and Excess,” Harrison’s Principle of Internal Medicine, 16th Edition, McGraw-Hill Companies, Inc., New York, 2005, pp. 403-411.
[8]	N. Buist and R. Steiner, “Disorder of Metal Metabolism,” In: A. G. Campbell and N. Mclntodh, Eds., Churchill Livingstone, 1998.
[9]	E. F. Rostan, H. V. De Buys, D. L. Madey and S. R. Pinnell, “Evidence Supporting Zinc as an Important Antioxidant for Skin,” International Journal of Dermatology, Vol. 41, No. 9, 2002, pp. 606-615. http://dx.doi.org/10.1046/j.1365-4362.2002.01567.x
[10]	K. E. Sharquie and K. K. Al-Azzawi, “Intralesional Therapy of Cutaneous Leishmaniasis with 2% Zinc Sulfate Solution,” Journal of Pan-Arab League of Dermatologists, Vol. 7, No. 2, 1996, pp. 41-49.
[11]	K. E. Sharquie and A. A. Al-Nuaimy, “Treatment of Viral Warts by Intralesional Injection of Zinc Sulfate,” Annals of Saudi Medicine, Vol. 22, No. 1-2, 2002, pp. 26-28.
[12]	K. E. Sharquie, A. A. Khorsheed and A. A. Al-Nuaimy, “Topical Zinc Sulphate Solution for Treatment of Viral Warts,” Saudi Medical Journal, Vol. 28, 2007, pp. 477480.
[13]	I. G. Al-Tereihi, “Topical 10% Zinc Sulphate Solution in the Treatment of Superficial Fungal Infections,” A Thesis Submitted to the Iraqi Board for Medical Specializations, Dermatology and Venereology, 2006.
[14]	K. E. Sharquie, W. S. Al-Dori, I. K. Sharquie and A. A. Al-Nuaimy, “Treatment of Pityriasis Versicolor with Topical 15% Zinc Sulfate Solution,” 15th Congress of the European Academy of Dermatology and Venereology, 2006.
[15]	K. E. Sharquie, R. A. Najim, I. B. Farjou and D. J. Al-Timimi, “Oral Zinc Sulphate in the Treatment of Acute Cutaneous Leishmaniasis,” Clinical and Experimental Dermatology, Vol. 26, 2001, pp. 21-25. http://dx.doi.org/10.1046/j.1365-2230.2001.00752.x
[16]	K. E. Sharquie, R. A. Najim and H. N. Al-Salman, “Oral Zinc Sulphate in the Treatment of Rosacea. A Double Blind Placebo-Controlled Cross-Over Study,” JEADV, Vol. 19, No. S2, 2005.
[17]	K. E. Sharquie, I. A. Al-Turfi and S. M. Sallom, “The Antibacterial Activity of Tea in Vitro and Vivo in Patients with Impetigo Contagiosa,” Journal of Dermatology, Vol. 27, 2000, pp. 706-710.
[18]	E. K. Sharquie, I. A. Al-Turfi and W. Al-Shimary, “Treatment of Acne Vulgaris 2% Topical Tea Lotion,” Saudi Medical Journal, Vol. 27, 2006, pp. 83-85.
[19]	S. Liao, “The Medicinal Action of Androgens and Green Tea Epigallocatechin Gallate,” Hong Kong Medical Journal, Vol. 7, No. 4, 2001, pp. 369-374.
[20]	K. E. Sharquie, A. A. Noaimi and M. M. Al-Salih, “Topical Therapy of Acne Vulgarisusing 2% Tea Lotion in Comparison with 5% Zinc Sulphate Solution,” Saudi Medical Journal, Vol. 29, 2008, pp. 1757-1761.
[21]	P. M. Mahjan, V. H. Jadhav, A. H. Patki, D. G. Jogaikar and J. M. Mehta, “Oral Zinc Therapy in Recurrent Erythema Nodosum Leprosum: A Clinical Study,” Indian Journal of Leprosy, Vol. 66, 1994, pp. 51-57.
[22]	F. Al-Gurairi, M. M. Al-Waiz and K. E. Sharquie, “Oral Zinc Sulphate in the Treatment of Recalcitrant Viral Warts: Randomizd Placebo-Controlled Clinical Trial,” British Journal of Dermatology, Vol. 146, No. 3, 2002, pp. 423-431. http://dx.doi.org/10.1046/j.1365-2133.2002.04617.x
[23]	O. J. Clermensen and J. Siggaard, “Psoriatic Arthritis Treated with Zinc Sulphate,” British Journal of Dermatology, Vol. 103, No. 4, 1980, pp. 411-415. http://dx.doi.org/10.1111/j.1365-2133.1980.tb07 264.x
[24]	A. S. Parsad, “Zinc Disorders,” In: J. Ston, Ed., Dermatology, Immunology, and Allergy, C.V. Mosbey & Co., St Louis, 1985, pp. 759-765.
[25]	I. R. Record, “Protection by Zinc against UVA and UVB Induce Cellular and Genomic Damage in Vivo and in Vitro,” Biological Trace Element Research, Vol. 53, No. 1-3, 1996, pp. 19-25. http://dx.doi.org/10.1007/BF02784541
[26]	S. K. Katiyar, “Skin Photoprotection by Green Tea: Antioxidant and Immunomodulatory Effects,” Current Drug Targets—Immune, Endocrine & Metabolic Disorders, Vol. 3, 2003, pp. 234-242.
[27]	S. K. Katiyar, “Green Tea Polyphenols Treatment to Human Skin Prevent Formation of Ultraviolet Light B-Induced Pyrimidine Dimmers in DNA,” Clinical Cancer Research, Vol. 6, No. 10, 2000, pp. 3864-3869.
[28]	K. Mutasunaga, T. W. Klein and H. Fridman, “Legionella Pneumophila Replication in Macrophages Inhibited by Selective Immunomodulatory Effect on Cytokine Formation by Epigallcatechingallat a Major from of Tea Catechines,” Infection and Immunity, Vol. 69, No. 6, 2001, pp. 3947-3953.
[29]	Y. H. Johan, “A Therapeutic Trial in Rosacea of Metronidazole and Azithromycin,” MSc Thesis, Department of Pharmacology, College of Medicine, University of Baghdad, 2004.
[30]	J. T. Bamford, B. A. Elliott and I. V. Haller, “Tacrolimus Effect on Rosacea,” Journal of the American Academy of Dermatology, Vol. 50, 2004, pp. 107-108.
[31]	A. K. Gupta, “Topical Metronidazole for Rosacea,” Skin Therapy Letter, Vol. 7, 2002, pp. 1-3,6.